nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—Progesterone—uterine cancer	0.157	0.222	CbGbCtD
Linagliptin—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.142	0.201	CbGbCtD
Linagliptin—ABCB1—Dactinomycin—uterine cancer	0.125	0.176	CbGbCtD
Linagliptin—CYP3A4—Progesterone—uterine cancer	0.0941	0.133	CbGbCtD
Linagliptin—ABCB1—Etoposide—uterine cancer	0.0703	0.0994	CbGbCtD
Linagliptin—ABCB1—Doxorubicin—uterine cancer	0.0479	0.0678	CbGbCtD
Linagliptin—CYP3A4—Etoposide—uterine cancer	0.0421	0.0596	CbGbCtD
Linagliptin—CYP3A4—Doxorubicin—uterine cancer	0.0287	0.0406	CbGbCtD
Linagliptin—DPP4—exocrine gland—uterine cancer	0.0145	0.152	CbGeAlD
Linagliptin—Pancreatitis acute—Progesterone—uterine cancer	0.0104	0.0529	CcSEcCtD
Linagliptin—Pancreatitis acute—Medroxyprogesterone Acetate—uterine cancer	0.00947	0.0479	CcSEcCtD
Linagliptin—DPP4—epithelium—uterine cancer	0.00632	0.066	CbGeAlD
Linagliptin—DPP4—uterine cervix—uterine cancer	0.00627	0.0654	CbGeAlD
Linagliptin—DPP4—smooth muscle tissue—uterine cancer	0.00609	0.0636	CbGeAlD
Linagliptin—DPP4—decidua—uterine cancer	0.00597	0.0623	CbGeAlD
Linagliptin—DPP4—renal system—uterine cancer	0.00586	0.0612	CbGeAlD
Linagliptin—DPP4—endometrium—uterine cancer	0.00567	0.0592	CbGeAlD
Linagliptin—DPP4—mammalian vulva—uterine cancer	0.00548	0.0573	CbGeAlD
Linagliptin—DPP4—uterus—uterine cancer	0.00522	0.0545	CbGeAlD
Linagliptin—DPP4—female reproductive system—uterine cancer	0.00469	0.049	CbGeAlD
Linagliptin—DPP4—female gonad—uterine cancer	0.00427	0.0446	CbGeAlD
Linagliptin—DPP4—vagina—uterine cancer	0.00425	0.0443	CbGeAlD
Linagliptin—Diabetes mellitus—Medroxyprogesterone Acetate—uterine cancer	0.00365	0.0185	CcSEcCtD
Linagliptin—Pain in extremity—Progesterone—uterine cancer	0.0035	0.0177	CcSEcCtD
Linagliptin—Infection—Carboplatin—uterine cancer	0.00325	0.0165	CcSEcCtD
Linagliptin—Hypoglycaemia—Medroxyprogesterone Acetate—uterine cancer	0.00325	0.0165	CcSEcCtD
Linagliptin—Pain in extremity—Medroxyprogesterone Acetate—uterine cancer	0.00317	0.0161	CcSEcCtD
Linagliptin—Nasopharyngitis—Progesterone—uterine cancer	0.00313	0.0158	CcSEcCtD
Linagliptin—Nasopharyngitis—Medroxyprogesterone Acetate—uterine cancer	0.00284	0.0144	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Progesterone—uterine cancer	0.00281	0.0142	CcSEcCtD
Linagliptin—Weight increased—Progesterone—uterine cancer	0.00275	0.0139	CcSEcCtD
Linagliptin—DPP4—lymph node—uterine cancer	0.00275	0.0287	CbGeAlD
Linagliptin—Infestation NOS—Progesterone—uterine cancer	0.0027	0.0137	CcSEcCtD
Linagliptin—Infestation—Progesterone—uterine cancer	0.0027	0.0137	CcSEcCtD
Linagliptin—Urinary tract infection—Progesterone—uterine cancer	0.00262	0.0133	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Medroxyprogesterone Acetate—uterine cancer	0.00255	0.0129	CcSEcCtD
Linagliptin—Weight increased—Medroxyprogesterone Acetate—uterine cancer	0.0025	0.0126	CcSEcCtD
Linagliptin—Infestation NOS—Medroxyprogesterone Acetate—uterine cancer	0.00244	0.0124	CcSEcCtD
Linagliptin—Infestation—Medroxyprogesterone Acetate—uterine cancer	0.00244	0.0124	CcSEcCtD
Linagliptin—Urinary tract infection—Medroxyprogesterone Acetate—uterine cancer	0.00238	0.012	CcSEcCtD
Linagliptin—Skin exfoliation—Etoposide—uterine cancer	0.00236	0.0119	CcSEcCtD
Linagliptin—Immune system disorder—Progesterone—uterine cancer	0.00219	0.0111	CcSEcCtD
Linagliptin—Mediastinal disorder—Progesterone—uterine cancer	0.00218	0.011	CcSEcCtD
Linagliptin—Malnutrition—Progesterone—uterine cancer	0.00211	0.0107	CcSEcCtD
Linagliptin—Back pain—Progesterone—uterine cancer	0.00204	0.0103	CcSEcCtD
Linagliptin—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00198	0.01	CcSEcCtD
Linagliptin—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00198	0.01	CcSEcCtD
Linagliptin—Angioedema—Progesterone—uterine cancer	0.00193	0.00975	CcSEcCtD
Linagliptin—Hyperlipidaemia—Epirubicin—uterine cancer	0.00192	0.00971	CcSEcCtD
Linagliptin—CYP3A4—renal system—uterine cancer	0.00191	0.02	CbGeAlD
Linagliptin—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.00191	0.00967	CcSEcCtD
Linagliptin—ABCB1—myometrium—uterine cancer	0.00186	0.0194	CbGeAlD
Linagliptin—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.00185	0.00935	CcSEcCtD
Linagliptin—Cough—Progesterone—uterine cancer	0.00184	0.00931	CcSEcCtD
Linagliptin—Myalgia—Progesterone—uterine cancer	0.0018	0.00908	CcSEcCtD
Linagliptin—Arthralgia—Progesterone—uterine cancer	0.0018	0.00908	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.00178	0.00902	CcSEcCtD
Linagliptin—Hyperlipidaemia—Doxorubicin—uterine cancer	0.00178	0.00898	CcSEcCtD
Linagliptin—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.00175	0.00883	CcSEcCtD
Linagliptin—Anaphylactic shock—Progesterone—uterine cancer	0.00172	0.00871	CcSEcCtD
Linagliptin—Infection—Progesterone—uterine cancer	0.00171	0.00865	CcSEcCtD
Linagliptin—Skin disorder—Progesterone—uterine cancer	0.00167	0.00846	CcSEcCtD
Linagliptin—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.00163	0.00823	CcSEcCtD
Linagliptin—Myalgia—Medroxyprogesterone Acetate—uterine cancer	0.00163	0.00823	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00162	0.00817	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Progesterone—uterine cancer	0.00157	0.00793	CcSEcCtD
Linagliptin—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.00156	0.00789	CcSEcCtD
Linagliptin—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00155	0.00784	CcSEcCtD
Linagliptin—CYP3A4—female reproductive system—uterine cancer	0.00153	0.016	CbGeAlD
Linagliptin—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00151	0.00766	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Progesterone—uterine cancer	0.00149	0.00752	CcSEcCtD
Linagliptin—Constipation—Progesterone—uterine cancer	0.00147	0.00745	CcSEcCtD
Linagliptin—ABCB1—epithelium—uterine cancer	0.00146	0.0152	CbGeAlD
Linagliptin—ABCB1—uterine cervix—uterine cancer	0.00145	0.0151	CbGeAlD
Linagliptin—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00142	0.00719	CcSEcCtD
Linagliptin—Infestation—Etoposide—uterine cancer	0.00138	0.00698	CcSEcCtD
Linagliptin—Infestation NOS—Etoposide—uterine cancer	0.00138	0.00698	CcSEcCtD
Linagliptin—ABCB1—decidua—uterine cancer	0.00138	0.0144	CbGeAlD
Linagliptin—Urticaria—Progesterone—uterine cancer	0.00137	0.00692	CcSEcCtD
Linagliptin—ABCB1—renal system—uterine cancer	0.00135	0.0141	CbGeAlD
Linagliptin—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00135	0.00681	CcSEcCtD
Linagliptin—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.00133	0.00675	CcSEcCtD
Linagliptin—Skin exfoliation—Epirubicin—uterine cancer	0.00132	0.00668	CcSEcCtD
Linagliptin—ABCB1—endometrium—uterine cancer	0.00131	0.0137	CbGeAlD
Linagliptin—Myalgia—Dactinomycin—uterine cancer	0.00127	0.00642	CcSEcCtD
Linagliptin—Hypersensitivity—Progesterone—uterine cancer	0.00127	0.00642	CcSEcCtD
Linagliptin—ABCB1—mammalian vulva—uterine cancer	0.00127	0.0132	CbGeAlD
Linagliptin—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00124	0.00627	CcSEcCtD
Linagliptin—Skin exfoliation—Doxorubicin—uterine cancer	0.00122	0.00618	CcSEcCtD
Linagliptin—Infection—Dactinomycin—uterine cancer	0.00121	0.00611	CcSEcCtD
Linagliptin—ABCB1—uterus—uterine cancer	0.00121	0.0126	CbGeAlD
Linagliptin—Diarrhoea—Progesterone—uterine cancer	0.00118	0.00596	CcSEcCtD
Linagliptin—Diabetes mellitus—Epirubicin—uterine cancer	0.00115	0.00584	CcSEcCtD
Linagliptin—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00115	0.00581	CcSEcCtD
Linagliptin—Immune system disorder—Etoposide—uterine cancer	0.00112	0.00566	CcSEcCtD
Linagliptin—Mediastinal disorder—Etoposide—uterine cancer	0.00112	0.00565	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00111	0.00561	CcSEcCtD
Linagliptin—Rash—Progesterone—uterine cancer	0.00108	0.00549	CcSEcCtD
Linagliptin—Dermatitis—Progesterone—uterine cancer	0.00108	0.00549	CcSEcCtD
Linagliptin—ABCB1—female reproductive system—uterine cancer	0.00108	0.0113	CbGeAlD
Linagliptin—Headache—Progesterone—uterine cancer	0.00108	0.00546	CcSEcCtD
Linagliptin—Diabetes mellitus—Doxorubicin—uterine cancer	0.00107	0.0054	CcSEcCtD
Linagliptin—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00107	0.0054	CcSEcCtD
Linagliptin—Back pain—Etoposide—uterine cancer	0.00104	0.00528	CcSEcCtD
Linagliptin—Hypoglycaemia—Epirubicin—uterine cancer	0.00103	0.00521	CcSEcCtD
Linagliptin—Pain in extremity—Epirubicin—uterine cancer	0.001	0.00508	CcSEcCtD
Linagliptin—ABCB1—female gonad—uterine cancer	0.000986	0.0103	CbGeAlD
Linagliptin—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000983	0.00498	CcSEcCtD
Linagliptin—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000982	0.00497	CcSEcCtD
Linagliptin—ABCB1—vagina—uterine cancer	0.00098	0.0102	CbGeAlD
Linagliptin—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000977	0.00494	CcSEcCtD
Linagliptin—Hypoglycaemia—Doxorubicin—uterine cancer	0.000952	0.00482	CcSEcCtD
Linagliptin—Cough—Etoposide—uterine cancer	0.000941	0.00476	CcSEcCtD
Linagliptin—Pain in extremity—Doxorubicin—uterine cancer	0.000929	0.0047	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000912	0.00462	CcSEcCtD
Linagliptin—Nasopharyngitis—Epirubicin—uterine cancer	0.000898	0.00454	CcSEcCtD
Linagliptin—Hypersensitivity—Dactinomycin—uterine cancer	0.000896	0.00453	CcSEcCtD
Linagliptin—Anaphylactic shock—Etoposide—uterine cancer	0.00088	0.00445	CcSEcCtD
Linagliptin—Infection—Etoposide—uterine cancer	0.000875	0.00443	CcSEcCtD
Linagliptin—Skin disorder—Etoposide—uterine cancer	0.000855	0.00433	CcSEcCtD
Linagliptin—Pancreatitis—Epirubicin—uterine cancer	0.000851	0.00431	CcSEcCtD
Linagliptin—Diarrhoea—Dactinomycin—uterine cancer	0.000832	0.00421	CcSEcCtD
Linagliptin—Nasopharyngitis—Doxorubicin—uterine cancer	0.000831	0.0042	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000806	0.00408	CcSEcCtD
Linagliptin—Weight increased—Epirubicin—uterine cancer	0.00079	0.004	CcSEcCtD
Linagliptin—Pancreatitis—Doxorubicin—uterine cancer	0.000787	0.00398	CcSEcCtD
Linagliptin—Infestation NOS—Epirubicin—uterine cancer	0.000774	0.00392	CcSEcCtD
Linagliptin—Infestation—Epirubicin—uterine cancer	0.000774	0.00392	CcSEcCtD
Linagliptin—Rash—Dactinomycin—uterine cancer	0.000767	0.00388	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Etoposide—uterine cancer	0.00076	0.00385	CcSEcCtD
Linagliptin—Constipation—Etoposide—uterine cancer	0.000753	0.00381	CcSEcCtD
Linagliptin—Urinary tract infection—Epirubicin—uterine cancer	0.000752	0.00381	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000746	0.00378	CcSEcCtD
Linagliptin—Weight increased—Doxorubicin—uterine cancer	0.000731	0.0037	CcSEcCtD
Linagliptin—Infestation NOS—Doxorubicin—uterine cancer	0.000716	0.00362	CcSEcCtD
Linagliptin—Infestation—Doxorubicin—uterine cancer	0.000716	0.00362	CcSEcCtD
Linagliptin—Urticaria—Etoposide—uterine cancer	0.000699	0.00354	CcSEcCtD
Linagliptin—Urinary tract infection—Doxorubicin—uterine cancer	0.000696	0.00352	CcSEcCtD
Linagliptin—Hypersensitivity—Etoposide—uterine cancer	0.000649	0.00328	CcSEcCtD
Linagliptin—ABCB1—lymph node—uterine cancer	0.000634	0.00662	CbGeAlD
Linagliptin—Immune system disorder—Epirubicin—uterine cancer	0.000627	0.00317	CcSEcCtD
Linagliptin—Mediastinal disorder—Epirubicin—uterine cancer	0.000626	0.00317	CcSEcCtD
Linagliptin—Malnutrition—Epirubicin—uterine cancer	0.000605	0.00306	CcSEcCtD
Linagliptin—Diarrhoea—Etoposide—uterine cancer	0.000602	0.00305	CcSEcCtD
Linagliptin—Back pain—Epirubicin—uterine cancer	0.000585	0.00296	CcSEcCtD
Linagliptin—Immune system disorder—Doxorubicin—uterine cancer	0.00058	0.00294	CcSEcCtD
Linagliptin—Mediastinal disorder—Doxorubicin—uterine cancer	0.000579	0.00293	CcSEcCtD
Linagliptin—Malnutrition—Doxorubicin—uterine cancer	0.000559	0.00283	CcSEcCtD
Linagliptin—Rash—Etoposide—uterine cancer	0.000555	0.00281	CcSEcCtD
Linagliptin—Dermatitis—Etoposide—uterine cancer	0.000555	0.00281	CcSEcCtD
Linagliptin—Headache—Etoposide—uterine cancer	0.000551	0.00279	CcSEcCtD
Linagliptin—Back pain—Doxorubicin—uterine cancer	0.000541	0.00274	CcSEcCtD
Linagliptin—Cough—Epirubicin—uterine cancer	0.000528	0.00267	CcSEcCtD
Linagliptin—Myalgia—Epirubicin—uterine cancer	0.000515	0.0026	CcSEcCtD
Linagliptin—Arthralgia—Epirubicin—uterine cancer	0.000515	0.0026	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000511	0.00259	CcSEcCtD
Linagliptin—Anaphylactic shock—Epirubicin—uterine cancer	0.000493	0.0025	CcSEcCtD
Linagliptin—Infection—Epirubicin—uterine cancer	0.00049	0.00248	CcSEcCtD
Linagliptin—Cough—Doxorubicin—uterine cancer	0.000488	0.00247	CcSEcCtD
Linagliptin—Skin disorder—Epirubicin—uterine cancer	0.000479	0.00243	CcSEcCtD
Linagliptin—Myalgia—Doxorubicin—uterine cancer	0.000476	0.00241	CcSEcCtD
Linagliptin—Arthralgia—Doxorubicin—uterine cancer	0.000476	0.00241	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000473	0.00239	CcSEcCtD
Linagliptin—Anaphylactic shock—Doxorubicin—uterine cancer	0.000457	0.00231	CcSEcCtD
Linagliptin—Infection—Doxorubicin—uterine cancer	0.000454	0.0023	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.00045	0.00228	CcSEcCtD
Linagliptin—Skin disorder—Doxorubicin—uterine cancer	0.000443	0.00224	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000426	0.00216	CcSEcCtD
Linagliptin—Constipation—Epirubicin—uterine cancer	0.000422	0.00214	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000416	0.00211	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000394	0.00199	CcSEcCtD
Linagliptin—Urticaria—Epirubicin—uterine cancer	0.000392	0.00198	CcSEcCtD
Linagliptin—Constipation—Doxorubicin—uterine cancer	0.00039	0.00198	CcSEcCtD
Linagliptin—Hypersensitivity—Epirubicin—uterine cancer	0.000364	0.00184	CcSEcCtD
Linagliptin—Urticaria—Doxorubicin—uterine cancer	0.000363	0.00184	CcSEcCtD
Linagliptin—Diarrhoea—Epirubicin—uterine cancer	0.000338	0.00171	CcSEcCtD
Linagliptin—Hypersensitivity—Doxorubicin—uterine cancer	0.000336	0.0017	CcSEcCtD
Linagliptin—Diarrhoea—Doxorubicin—uterine cancer	0.000312	0.00158	CcSEcCtD
Linagliptin—Rash—Epirubicin—uterine cancer	0.000311	0.00157	CcSEcCtD
Linagliptin—Dermatitis—Epirubicin—uterine cancer	0.000311	0.00157	CcSEcCtD
Linagliptin—Headache—Epirubicin—uterine cancer	0.000309	0.00156	CcSEcCtD
Linagliptin—Rash—Doxorubicin—uterine cancer	0.000288	0.00146	CcSEcCtD
Linagliptin—Dermatitis—Doxorubicin—uterine cancer	0.000288	0.00146	CcSEcCtD
Linagliptin—Headache—Doxorubicin—uterine cancer	0.000286	0.00145	CcSEcCtD
